The MHRA have issued new guidance on Cannabidiol. This week sees a new issue of the very useful MHRA’s ‘Guide to what is a Medicinal Product’. This is a primary document for products that fall within the borderline area. It sets out what the MHRA is thinking based on new legislation/cases they have assessed. The MHRA will never say if a category is or is not legal, as they always assess each product on a case by case basis. Cannabidiol is one such category that attracts much debate. Indeed, anyone attending the Pharmacy Show this month would have seen many vendors with non-medicinal hemp products.
In this October 2018 revised guide, the reader needs stamina as the changes are presented in Appendix 10, page 67. This appendix covers the MHRA position/guidance for Cannabidiol containing products, covering:
- CBD products for non-medical purposes
- Compliance with other regulatory frameworks
- CBD products for medical purposes
- Supply of an unlicensed medicine (a ‘Special’)
- Obtaining a licence to supply a licensed medicine